Author Archives: admin


Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transformative potential of artificial intelligence in the biopharma industry. Panelists will include Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare of Microsoft (Nasdaq: MSFT), Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, and Dr. Sean Tunis, Principal of Rubix Health.

See the rest here:
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

KENSINGTON, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the initiation of a Phase 2 study (eDREAM; NCT06659549) with GAL-101 eye drops in patients with dry age-related macular degeneration (dry AMD), a leading cause of adult blindness. The randomized, double-blind, placebo-controlled multicenter study will evaluate the efficacy and safety of GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

See more here:
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from studies demonstrating effectiveness of the RXR agonist compound IRX4204 in reversing demyelination, and functionally restoring movement in the paralyzed legs of mice subjected to an autoimmune-mediated demyelinating model of human multiple sclerosis (MS). The research report titled: “Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis”, G.D.S Kasheke, et al; was published in the December 21, 2024 edition of Acta Neuropathologica Communications.

Read the original:
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024.

More here:
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

See the rest here:
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited’s proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).

Read more from the original source:
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).

Original post:
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial